Type of leukemia-Acute Lymphoblastic Leukemia (ALL) Posts on Medivizor
Navigation Menu

Type of leukemia-Acute Lymphoblastic Leukemia (ALL) Posts on Medivizor

Comparing outcomes of donors for a second allogenic stem cell transplant for patients with acute lymphoblastic leukemia

Comparing outcomes of donors for a second allogenic stem cell transplant for patients with acute lymphoblastic leukemia

Posted by on Jul 25, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to compare outcomes of donor types for a second allogeneic stem cell transplant (alloSCT) in patients with relapsed acute lymphoblastic leukemia (ALL).  This study concluded that there is no major difference in overall survival between a matched unrelated donor (MUD) and a half-matched donor (HMD) in...

Read More

Inotuzumab ozogamicin with bosutinib for relapsed/refractory Philadelphia chromosome-positive ALL or lymphoid blast phase of CML

Inotuzumab ozogamicin with bosutinib for relapsed/refractory Philadelphia chromosome-positive ALL or lymphoid blast phase of CML

Posted by on Jun 27, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if a combination of inotuzumab ozogamicin (InO; Besponsa) and bosutinib (Bo; Bosulif) was safe and effective in patients with relapsed/refractory (r/r) Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) or lymphoid blast phase (BP) chronic myeloid leukemia...

Read More

Evaluating the effectiveness and safety of inotuzumab ozogamicin for patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Evaluating the effectiveness and safety of inotuzumab ozogamicin for patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Posted by on Apr 18, 2021 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of inotuzumab ozogamicin (Besponsa; INO) in patients with relapsed/refractory (r/r) acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The data showed that the treatment had good effectiveness and manageable side effects for these patients. Some background A high number...

Read More

Combining venetoclax and navitoclax with chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma

Combining venetoclax and navitoclax with chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma

Posted by on Mar 28, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of venetoclax (Venclexta) and low-dose navitoclax (ABT-263) in combination with chemotherapy in patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL).  This study concluded that this treatment option was well tolerated and...

Read More

Total body irradiation vs chemotherapy conditioning in children with acute lymphoblastic leukemia

Total body irradiation vs chemotherapy conditioning in children with acute lymphoblastic leukemia

Posted by on Jan 17, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if chemotherapy (CT) conditioning could replace total body irradiation (TBI) before stem cell transplant (SCT) in children with acute lymphoblastic leukemia (ALL).  This study concluded that TBI in combination with CT was safer and more effective than CT conditioning alone in these...

Read More

What factors are associated with improved outcomes for patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic transplantation?

What factors are associated with improved outcomes for patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic transplantation?

Posted by on Dec 29, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate allogeneic blood or marrow transplantation (alloBMT) with post-transplant cyclophosphamide (PTCy; Cytoxan) in patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).   This study concluded that patients alloBMT with PTCy in first complete remission (CR1) leads...

Read More

Tisagenlecleucel in a real world setting for patients with acute lymphoblastic leukemia and non-Hodgkin lymphoma

Tisagenlecleucel in a real world setting for patients with acute lymphoblastic leukemia and non-Hodgkin lymphoma

Posted by on Dec 5, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of tisagenlecleucel (TL; Kymriah) in a real-world setting as a treatment for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).   This study concluded that TL has similar effectiveness and improved safety in a real-world...

Read More

Total body irradiation and risk of breast cancer after transplantation in patients with leukemia-lymphoma

Total body irradiation and risk of breast cancer after transplantation in patients with leukemia-lymphoma

Posted by on Oct 3, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the association between total body irradiation and further breast cancer diagnosis in patients treated with blood or marrow transplantation for leukemia-lymphoma.  This study concluded that there is an association between the total body irradiation and an increased risk of breast cancer in certain...

Read More

Evaluating antithymocyte globulin in preventing graft-versus-host-disease after matched sibling donor transplantation

Evaluating antithymocyte globulin in preventing graft-versus-host-disease after matched sibling donor transplantation

Posted by on Aug 16, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the role of antithymocyte globulin in preventing graft-versus-host disease after matched sibling donor transplantation.  This study concluded that this treatment can reduce the occurrence of graft-versus-host-disease in these patients.   Some background One...

Read More

Cardiac function of survivors of childhood acute lymphoblastic leukemia treated with anthracyclines

Cardiac function of survivors of childhood acute lymphoblastic leukemia treated with anthracyclines

Posted by on Aug 9, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the heart function of acute lymphoblastic leukemia survivors who had been treated with anthracyclines. This study concluded that these patients had decreased heart function long after treatment. Some background Anthracyclines are a type of chemotherapy drug. Examples are daunorubicin...

Read More